Rep. Thomas H. Kean, Jr. Sells Shares of Johnson & Johnson (NYSE:JNJ)

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on August 27th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 7/22/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 7/22/2026.
• Purchased $1,001 – $15,000 in shares of Toast (NYSE:TOST) on 7/8/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 7/8/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 7/7/2026.
• Purchased $1,001 – $15,000 in shares of EQT (NYSE:EQT) on 7/7/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 6/30/2026.

Johnson & Johnson Price Performance

NYSE JNJ opened at $266.81 on Tuesday. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $281.07. The stock’s 50-day moving average price is $263.18 and its two-hundred day moving average price is $246.08. The company has a market cap of $642.99 billion, a PE ratio of 30.92, a PEG ratio of 2.54 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Insider Transactions at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last ninety days. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising oncology data: J&J reported that RYBREVANT plus chemotherapy produced a median overall survival of 34.3 months in EGFR exon 20 insertion-positive lung cancer, described as the longest reported result for this population. The data could strengthen RYBREVANT’s commercial position and support future oncology growth. RYBREVANT survival data
• Positive Sentiment: Improved treatment experience for RYBREVANT: New COPERNICUS data showed low rates of rash, blood clots and administration-related reactions with subcutaneous RYBREVANT FASPRO plus LAZCLUZE; fewer than 1% of patients discontinued treatment because of treatment-related events at one year. This may improve adoption and broaden the therapy’s appeal. RYBREVANT FASPRO COPERNICUS results
• Positive Sentiment: Analyst support and possible DePuy Synthes sale: TD Cowen maintained a Buy rating with a $300 price target, citing oncology momentum and a potential roughly $20 billion divestiture of DePuy Synthes. A sale could unlock value, simplify J&J’s portfolio and provide capital for acquisitions or shareholder returns. TD Cowen J&J rating
• Positive Sentiment: Defensive-income appeal: Articles continue to highlight J&J as a long-term dividend holding, which may attract investors seeking stable, growing income amid broader market concerns and technology-sector volatility. Dividend stocks article
• Neutral Sentiment: J&J has identified a potential growth path despite expected biosimilar competition for STELARA, targeting double-digit growth through its broader pharmaceutical and medical-device portfolio. Execution and replacement of STELARA revenue remain key considerations. J&J growth targets
• Negative Sentiment: Depression-drug setback: J&J’s partnered experimental drug JNJ-5120, or PIPE-307, failed to meet the primary endpoint in a mid-stage major depressive disorder study. The result weakens the pipeline opportunity and contributed to pressure on partner Contineum Therapeutics. Depression drug trial failure
• Negative Sentiment: J&J’s requirement that providers share claims data to receive 340B discounts could create compliance concerns and increase friction with hospitals and policymakers. 340B claims-data requirement

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors have recently bought and sold shares of the stock. Bullseye Investment Management LLC bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $63,000. Talon Private Wealth LLC boosted its holdings in Johnson & Johnson by 89.5% in the 2nd quarter. Talon Private Wealth LLC now owns 10,588 shares of the company’s stock valued at $2,689,000 after purchasing an additional 5,002 shares during the period. U S Wealth Group LLC. grew its position in Johnson & Johnson by 15.1% in the 2nd quarter. U S Wealth Group LLC. now owns 17,259 shares of the company’s stock worth $4,383,000 after purchasing an additional 2,266 shares during the last quarter. Miramontes Capital LLC increased its holdings in shares of Johnson & Johnson by 20.5% during the 2nd quarter. Miramontes Capital LLC now owns 7,584 shares of the company’s stock worth $1,926,000 after purchasing an additional 1,289 shares during the period. Finally, Core Capital Management & Research inc. acquired a new position in shares of Johnson & Johnson during the second quarter valued at about $1,087,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on JNJ. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Citigroup boosted their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, HSBC increased their price objective on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $274.13.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.